Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Biocatalyst product sales	$ 4,052	$ 1,818	$ 11,072	$ 6,915
Biocatalyst research and development	10,373	14,517	25,971	19,247
Revenue sharing arrangement	445	1,066	1,825	4,056
Total revenues	14,870	17,401	38,868	30,218
Costs and operating expenses:
Cost of biocatalyst product sales	2,756	1,302	7,466	4,009
Research and development	5,467	4,994	16,265	15,457
Selling, general and administrative	5,229	5,415	18,451	16,289
Total costs and operating expenses	13,452	11,711	42,182	35,755
Income (loss) from operations	1,418	5,690	(3,314)	(5,537)
Interest income	12	4	40	12
Other income (expenses)	7	(26)	(39)	(147)
Income (loss) before income taxes	1,437	5,668	(3,313)	(5,672)
Provision for (benefit from) income taxes	0	274	(15)	(144)
Net income (loss)	$ 1,437	$ 5,394	$ (3,298)	$ (5,528)
Net income (loss) per share, basic (usd per share)	$ 0.04	$ 0.14	$ (0.08)	$ (0.14)
Net income (loss) per share, diluted (usd per share)	$ 0.03	$ 0.13	$ (0.08)	$ (0.14)
Weighted average common stock shares used in computing net income (loss) per share, basic (shares)	40,940	39,767	40,504	39,340
Weighted average common stock shares used in computing net income (loss) per share, diluted (shares)	42,134	40,970	40,504	39,340